Bulk Manufacturer of Controlled Substances Application: National Center for Natural Products Research, 63090-63091 [2022-22579]
Download as PDF
<![CDATA[
63090
Federal Register / Vol. 87, No. 200 / Tuesday, October 18, 2022 / Notices
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 731–TA–1315 (Review)]
Ferrovanadium From South Korea;
Scheduling of an Expedited Five-Year
Review
International Trade
Commission.
ACTION: Notice.
AGENCY:
The Commission hereby gives
notice of the scheduling of an expedited
review pursuant to the Tariff Act of
1930 (‘‘the Act’’) to determine whether
revocation of the antidumping duty
order on ferrovanadium from South
Korea would be likely to lead to
continuation or recurrence of material
injury within a reasonably foreseeable
time.
DATES: July 5, 2022.
FOR FURTHER INFORMATION CONTACT:
Keysha Martinez (202–205–2136), Office
of Investigations, U.S. International
Trade Commission, 500 E Street SW,
Washington, DC 20436. Hearingimpaired persons can obtain
information on this matter by contacting
the Commission’s TDD terminal on 202–
205–1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
of the Secretary at 202–205–2000.
General information concerning the
Commission may also be obtained by
accessing its internet server (https://
www.usitc.gov). The public record for
this review may be viewed on the
Commission’s electronic docket (EDIS)
at https://edis.usitc.gov.
SUPPLEMENTARY INFORMATION:
Background.—On July 5, 2022, the
Commission determined that the
domestic interested party group
response to its notice of institution (87
FR 19129, April 1, 2022) of the subject
five-year review was adequate and that
the respondent interested party group
response was inadequate. The
Commission did not find any other
circumstances that would warrant
conducting a full review.1 Accordingly,
the Commission determined that it
would conduct an expedited review
pursuant to section 751(c)(3) of the
Tariff Act of 1930 (19 U.S.C. 1675(c)(3)).
For further information concerning
the conduct of this review and rules of
general application, consult the
Commission’s Rules of Practice and
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
1 A record of the Commissioners’ votes, the
Commission’s statement on adequacy, and any
individual Commissioner’s statements will be
available from the Office of the Secretary and at the
Commission’s website.
VerDate Sep<11>2014
19:52 Oct 17, 2022
Jkt 259001
Procedure, part 201, subparts A and B
(19 CFR part 201), and part 207,
subparts A, D, E, and F (19 CFR part
207).
Staff report.—A staff report
containing information concerning the
subject matter of the review has been
placed in the nonpublic record, and will
be made available to persons on the
Administrative Protective Order service
list for this review on October 14, 2022.
A public version will be issued
thereafter, pursuant to § 207.62(d)(4) of
the Commission’s rules.
Written submissions.—As provided in
§ 207.62(d) of the Commission’s rules,
interested parties that are parties to the
review and that have provided
individually adequate responses to the
notice of institution,2 and any party
other than an interested party to the
review may file written comments with
the Secretary on what determination the
Commission should reach in the review.
Comments are due on or before October
21, 2022 and may not contain new
factual information. Any person that is
neither a party to the five-year review
nor an interested party may submit a
brief written statement (which shall not
contain any new factual information)
pertinent to the review by October 21,
2022. However, should the Department
of Commerce (‘‘Commerce’’) extend the
time limit for its completion of the final
results of its review, the deadline for
comments (which may not contain new
factual information) on Commerce’s
final results is three business days after
the issuance of Commerce’s results. If
comments contain business proprietary
information (BPI), they must conform
with the requirements of §§ 201.6,
207.3, and 207.7 of the Commission’s
rules. The Commission’s Handbook on
Filing Procedures, available on the
Commission’s website at https://
www.usitc.gov/documents/handbook_
on_filing_procedures.pdf, elaborates
upon the Commission’s procedures with
respect to filings.
In accordance with §§ 201.16(c) and
207.3 of the rules, each document filed
by a party to the review must be served
on all other parties to the review (as
identified by either the public or BPI
service list), and a certificate of service
must be timely filed. The Secretary will
not accept a document for filing without
a certificate of service.
Determination.—The Commission has
determined this review is
2 The Commission has found the responses
submitted by AMG Vanadium LLC, a U.S. producer,
U.S. Vanadium LLC, a U.S. wholesaler, and the
Vanadium Producers and Reclaimers Association, a
U.S. trade association, to be individually adequate.
Comments from other interested parties will not be
accepted (see 19 CFR 207.62(d)(2)).
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
extraordinarily complicated and
therefore has determined to exercise its
authority to extend the review period by
up to 90 days pursuant to 19 U.S.C.
1675(c)(5)(B).
Authority: This review is being
conducted under authority of title VII of
the Tariff Act of 1930; this notice is
published pursuant to § 207.62 of the
Commission’s rules.
By order of the Commission.
Issued: October 12, 2022.
Katherine Hiner,
Acting Secretary to the Commission.
[FR Doc. 2022–22560 Filed 10–17–22; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1100]
Bulk Manufacturer of Controlled
Substances Application: National
Center for Natural Products Research
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
National Center for Natural
Products Research has applied to be
registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before December 19, 2022. Such
persons may also file a written request
for a hearing on the application on or
before December 19, 2022.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUMMARY:
E:\FR\FM\18OCN1.SGM
18OCN1
63091
Federal Register / Vol. 87, No. 200 / Tuesday, October 18, 2022 / Notices
In
accordance with 21 CFR 1301.33(a), this
is notice that on September 12, 2022,
National Center for Natural Products
SUPPLEMENTARY INFORMATION:
Research, Coy Waller Research Center,
806 Hathorn Road, University,
Mississippi 38677–1848, applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substance(s):
Controlled substance
Drug code
Marihuana Extract ...........................................................................................................................................................
Marihuana ........................................................................................................................................................................
Tetrahydrocannabinols ....................................................................................................................................................
Drug Enforcement Administration
Eastern Time on the last day of the
comment period.
Based on comments received in
response to this notice, the
Administrator may hold a public
hearing on one or more issues raised. In
the event the Administrator decides in
her sole discretion to hold such a
hearing, the Administrator will publish
a notice of any such hearing in the
Federal Register. After consideration of
any comments or objections, or after a
hearing, if one is held, the
Administrator will publish in the
Federal Register a final order
establishing the 2023 aggregate
production quotas for schedule I and II
controlled substances, and an
assessment of annual needs for the list
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine.
[Docket No. DEA–1051P]
ADDRESSES:
The company plans to manufacture
the listed controlled substances for
product development and reference
standards. In reference to drug codes
7360 (Marihuana) and 7370
(Tetrahydrocannabinols), the company
plans to isolate these controlled
substances from procured 7350
(Marihuana Extract). In reference to
drug code 7360, no cultivation activities
are authorized for this registration. No
other activities for these drug codes are
authorized for this registration.
Kristi O’Malley,
Assistant Administrator.
[FR Doc. 2022–22579 Filed 10–17–22; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Proposed Aggregate Production
Quotas for Schedule I and II Controlled
Substances and Assessment of
Annual Needs for the List I Chemicals
Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2023
Drug Enforcement
Administration, Department of Justice.
ACTION: Notice with request for
comments.
AGENCY:
The Drug Enforcement
Administration (DEA) proposes to
establish the 2023 aggregate production
quotas for controlled substances in
schedules I and II of the Controlled
Substances Act (CSA) and the
assessment of annual needs for the list
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine.
SUMMARY:
Interested persons may file
written comments on this notice in
accordance with 21 CFR 1303.11(c) and
1315.11(d). Electronic comments must
be submitted, and written comments
must be postmarked, on or before
November 17, 2022. Commenters should
be aware that the electronic Federal
Docket Management System will not
accept comments after 11:59 p.m.
khammond on DSKJM1Z7X2PROD with NOTICES
DATES:
VerDate Sep<11>2014
19:52 Oct 17, 2022
Jkt 259001
To ensure proper handling
of comments, please reference ‘‘Docket
No. DEA–1051P’’ on all correspondence,
including any attachments. DEA
encourages that all comments be
submitted electronically through the
Federal eRulemaking Portal, which
provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to https://
www.regulations.gov and follow the
online instructions at that site for
submitting comments. Upon completion
of your submission, you will receive a
Comment Tracking Number for your
comment.
Please be aware that submitted
comments are not instantaneously
available for public view on
Regulations.gov. If you have received a
Comment Tracking Number, your
comment has been successfully
submitted, and there is no need to
resubmit the same comment. Paper
comments that duplicate electronic
submissions are not necessary and are
discouraged. Should you wish to mail a
paper comment in lieu of an electronic
comment, it should be sent via regular
or express mail to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
7350
7360
7370
Schedule
I
I
I
Morrissette Drive, Springfield, Virginia
22152.
FOR FURTHER INFORMATION CONTACT:
Scott A. Brinks, Regulatory Drafting and
Policy Support Section, Diversion
Control Division, Drug Enforcement
Administration; Mailing Address: 8701
Morrissette Drive, Springfield, Virginia
22152, Telephone: (571) 776–3882.
SUPPLEMENTARY INFORMATION:
Posting of Public Comments
Please note that all comments
received in response to this docket are
considered part of the public record.
They will, unless reasonable cause is
given, be made available by the Drug
Enforcement Administration (DEA) for
public inspection online at https://
www.regulations.gov. Such information
includes personal identifying
information (such as your name,
address, etc.) voluntarily submitted by
the commenter.
The Freedom of Information Act
applies to all comments received. If you
want to submit personal identifying
information (such as your name,
address, etc.) as part of your comment,
but do not want it to be made publicly
available, you must include the phrase
‘‘PERSONAL IDENTIFYING
INFORMATION’’ in the first paragraph
of your comment. You must also place
all the personal identifying information
you do not want made publicly
available in the first paragraph of your
comment and identify what information
you want redacted.
If you want to submit confidential
business information as part of your
comment, but do not want it to be made
publicly available, you must include the
phrase ‘‘CONFIDENTIAL BUSINESS
INFORMATION’’ in the first paragraph
of your comment. You must also
prominently identify confidential
business information to be redacted
within the comment.
Comments containing personal
identifying information or confidential
business information identified and
located as directed above will generally
be made available in redacted form. If a
comment contains so much confidential
business information or personal
E:\FR\FM\18OCN1.SGM
18OCN1
]]>Agencies
[Federal Register Volume 87, Number 200 (Tuesday, October 18, 2022)]
[Notices]
[Pages 63090-63091]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-22579]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1100]
Bulk Manufacturer of Controlled Substances Application: National
Center for Natural Products Research
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: National Center for Natural Products Research has applied to
be registered as a bulk manufacturer of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for
further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
December 19, 2022. Such persons may also file a written request for a
hearing on the application on or before December 19, 2022.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment.
[[Page 63091]]
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on September 12, 2022, National Center for Natural
Products Research, Coy Waller Research Center, 806 Hathorn Road,
University, Mississippi 38677-1848, applied to be registered as a bulk
manufacturer of the following basic class(es) of controlled
substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Marihuana Extract........................ 7350 I
Marihuana................................ 7360 I
Tetrahydrocannabinols.................... 7370 I
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
for product development and reference standards. In reference to drug
codes 7360 (Marihuana) and 7370 (Tetrahydrocannabinols), the company
plans to isolate these controlled substances from procured 7350
(Marihuana Extract). In reference to drug code 7360, no cultivation
activities are authorized for this registration. No other activities
for these drug codes are authorized for this registration.
Kristi O'Malley,
Assistant Administrator.
[FR Doc. 2022-22579 Filed 10-17-22; 8:45 am]
BILLING CODE P
